Gherelin: Endocrine and non-endocrine actions

Journal of Pediatric Endocrinology and Metabolism

Volumn 15, Issue SUPPL. 5, 2002, Pages 1219-1227

  Broglio, Fabio ^a   Arvat, Emanuela ^a   Benso, Andrea ^a   Papotti, Mauro ^b   Muccioli, Giampiero ^b   Deghenghi, Romano ^c   Ghigo, Ezio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Ardana   (France)

Author keywords

Cancer; Cardiovascular system; Food intake; Ghrelin; Growth hormone; Growth hormone secretagogues; Insulin like growth factor I; Metabolism

Indexed keywords

4 AMINOBUTYRIC ACID; ALENDRONIC ACID; AMINO ACID DERIVATIVE; ANABOLIC AGENT; ARGININE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; FATTY ACID; GASTROINTESTINAL POLYPEPTIDE; GHRELIN; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE SECRETAGOGUE; GROWTH HORMONE SECRETAGOGUE RECEPTOR; HEXAPEPTIDE; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; IBUTAMOREN; NALOXONE; NEUROPEPTIDE Y; PROLACTIN; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; SOMATOSTATIN; UNINDEXED DRUG; VASOPRESSIN; INDOLE DERIVATIVE; PEPTIDE HORMONE; SPIRO COMPOUND;

AGING; AMINO ACID ANALYSIS; ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CORTICOTROPIN RELEASE; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG USE; GASTROINTESTINAL TRACT FUNCTION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; NONHUMAN; PANCREAS FUNCTION; PERIPHERAL NERVOUS SYSTEM; PROLACTIN RELEASE; ANIMAL; BLOOD; CARDIOVASCULAR SYSTEM; DRUG EFFECT; ENDOCRINE GLAND; ENERGY METABOLISM; GONAD; REVIEW; SECRETION;

ANIMALS; CARDIOVASCULAR SYSTEM; ENDOCRINE GLANDS; ENERGY METABOLISM; GONADS; GROWTH HORMONE; HUMANS; INDOLES; PEPTIDE HORMONES; PROLACTIN; SPIRO COMPOUNDS;

EID: 0038106210     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ Jr, Fisher MH, Nargund RP, Patchett AA. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997; 18: 621-645.
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
3. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2001; 2: 551-560.
4. Kojima M, Hosoda H, Matsuo H, Kangawa K. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 2001; 12: 118-122.
5. Smith RG, Leonard R, Bailey AR, Palyha O, Feighner S, Tan C, Mckee KK, Pong SS, Griffin P, Howard A. Growth hormone secretagogue receptor family members and ligands. Endocrine 2001; 14: 9-14.
6. Muccioli G, Tschop M, Papotti M, Deghenghi R, Hieman M, Ghigo E. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol 2002; 440: 235-254.
7. Ghigo E, Arvat E, Giordano R, Broglio F, Gianotti L, Maccario M, Bisi G, Graziani A, Papotti M, Muccioli G, Deghenghi R, Camanni F. Biologic activities of growth hormone secretagogues in humans. Endocrine 2001; 14: 87-93.
8. Arvat E, Di Vito L, Broglio F, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E. Preliminary evidence that ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest 2000; 23: 493-495.
9. Arvat E, Maccario M, Di Vito L, Broglio F, Benso A, Gottero C, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Camanni F, Ghigo E. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab 2001; 86: 1169-1174.
10. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 2000; 85: 4908-4911.
11. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffith PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-977.
12. 125I-labeled ghrelin to membranes from human hypothalamus and pituitary gland. J Endocrinol Invest 2001; 24: RC7-9.
13. Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-1719.
14. Tschop M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML. Circulating ghrelin levels are decreased in human obesity. Diabetes 2001; 50: 707-709.
15. Muller A, Lamberts SWJ, Janssen JAMJL, Hofland L, van Koetsveld P, Bidlingmaier M, Strasburger CJ, Ghigo E, van der Lely AJ. Ghrelin drives growth hormone secretion during fasting in man. Eur J Endocrinol 2002; 146: 203-207.
16. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87: 240-244.
17. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346: 1623-1630.
18. Flier JS, Maratos-Flier E. The stomach speaks - ghrelin and weight regulation. N Engl J Med 2002; 346: 1662-1663.
19. Tannenbaum GS, Bowers CY. Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin. Endocrine 2001; 14: 21-27.
20. Baldelli R, Otero XL, Camina JP, Gualillo O, Popovic V, Dieguez C, Casanueva FF. Growth hormone secretagogues as diagnostic tools in disease states. Endocrine 2001; 14: 95-99.
21. Yu H, Cassorla F, Tiulpakov A, Shi Y-F, Setian N, Bercu B, Arango A, Kletter G, Pescovitz O, Di Martino J, Krupa D, Cambria M, Kanojia P, Bach MA. A double-blind placebo-controlled efficacy trial of an oral growth hormone (GH) secretagogue (MK-0677) in GH deficient (GHD) children. In: 80th Annual Meeting of the Endocrine Society, New Orleans, LA, USA, June, 1998; 84 (OR24-6).
22. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39.
23. Ghigo E, Arvat E, Gianotti L, Ramunni J, DiVito L, Maccagno B, Grottoli S, Camanni F. Human aging and the GH-IGF-I axis. J Pediatr Endocrinol Metab 1996; 9 (Suppl 3): 271-278.
24. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249-4257.
25. Copinschi G, Leproult R, Van Onderbergen A, Caufriez A, Cole KY, Schilling LM, Mendel CM, De Lepeleire I, Bolognese JA, Van Cauter E. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology 1997; 66: 278-286.
26. Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab 1998; 83: 320-325.
27. Svensson J, Lonn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjostrom L, Bengtsson BA. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab 1998; 83: 362-369.
28. Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab 2001; 86: 1116-1125.
29. De Keyzer Y, Lenne F, Bertagna X. Widespread transcription of the growth hormone-releasing peptide receptor gene in neuroendocrine human tumors. Eur J Endocrinol 1997; 137: 715-718.
30. Kim K, Arai K, Sanno N, Osamura RY, Teramoto A, Shibasaki T. Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas. Clin Endocrinol (Oxf) 2001; 54: 759-768.
31. Korbonits M, Bustin SA, Kojima M, Jordan S, Adams EF, Lowe DG, Kangawa K, Grossman AB. The expression of the growth hormone secretagogue receptor ligand ghrelin in normal and abnormal human pituitary and other neuroendocrine tumors. J Clin Endocrinol Metab 2001; 86: 881-887.
32. Tena-Sempere M, Barreiro ML, Gonzalez LC, Gaytan F, Zhang FP, Caminos JE, Pinilla L, Casanueva FF, Dieguez C, Aguilar E. Novel expression and functional role of ghrelin in rat testis. Endocrinology 2002; 143: 717-725.
33. Furuta M, Funabashi T, Kimura F. Intracerebroventricular administration of ghrelin rapidly suppresses pulsatile luteinizing hormone secretion in ovariectomized rats. Biochem Biophys Res Commun 2001; 288: 780-785.
34. Horvath TL, Diano S, Sotonyi P, Heiman M, Tschop M. Minireview: Ghrelin and the regulation of energy balance - a hypothalamic perspective. Endocrinology 2001; 142: 4163-4169.
35. Papotti M, Cassoni P, Volante M, Deghenghi R, Muccioli G, Ghigo E. Ghrelin-producing endocrine tumors of the stomach and intestine. J Clin Endocrinol Metab 2001; 86: 5052-5059.
36. Volante M, Allìa E, Gugliotta P, Funaro A, Broglio F, Deghenghi R, Muccioli G, Ghigo E, Papotti M. Expression of ghrelin and of GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2001; 87: 1300-1308.
37. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, Suda M, Koh T, Natsui K, Toyooka S, Shirakami G, Usui T, Shimatsu A, Doi K, Hosoda H, Kojima M, Kangawa K, Nakao K. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-4758.
38. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-5086.
39. De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller EE, Berti F. Hexarelin, a growth hormone-releasing peptide, discloses protectant activity against cardiovascular damage in rats with isolated growth hormone deficiency. Cardiologia 1997; 42: 1165-1172.
40. Rossoni G, De Gennaro Colonna V, Bernareggi M, Polvani GL, Muller EE, Berti F. Protectant activity of hexarelin or growth hormone against postischemic ventricular dysfunction in hearts from aged rats. J Cardiovasc Pharmacol 1998; 32: 260-265.
41. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, Bernareggi M, Deghenghi R, Muller EE, Berti F. Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 1999; 140: 4024-4031.
42. Tivesten A, Bollano E, Caidahl K, Kujacic V, Sun XY, Hedner T, Hjalmarson A, Bengtsson BA, Isgaard J. The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction. Endocrinology 2000; 141: 60-66.
43. Weekers F, Van Herck E, Isgaard J, Van den Berghe G. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Endocrinology 2000; 141: 3993-3999.
44. King MK, Gay DM, Pan LC, McElmurray JH III, Hendrick JW, Pirie C, Morrison A, Ding C, Mukherjee R, Spinale FG. Treatment with a growth hormone secretagogue in a model of developing heart failure: effects on ventricular and myocyte function. Circulation 2001; 103: 308-313.
45. Bodart V, Bouchard JF, McNicoll N, Escher E, Carriere P, Ghigo E, Sejlitz T, Sirois MG, Lamontagne D, Ong H. Identification and characterization of a new growth hormone-releasing peptide receptor in the heart. Circ Res 1999; 85: 796-802.
46. Broglio F, Benso A, Valetto MR, Gottero C, Quaranta L, Podio V, Arvat E, Bobbio M, Bisi G, Ghigo E. Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy. Endocrine 2001; 14: 105-108.
47. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, Hayashi Y, Kangawa K. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: R1483-1487.
48. Kanamoto N, Akamizu T, Hosoda H, Hataya Y, Ariyasu H, Takaya K, Hosoda K, Saijo M, Moriyama K, Shimatsu A, Kojima M, Kangawa K, Nakao K. Substantial production of ghrelin by a human medullary thyroid carcinoma cell line. J Clin Endocrinol Metab 2001; 86: 4984-4990.